Trevi Therapeutics, Inc. (TRVI)Healthcare | Biotechnology | New Haven, United States | NasdaqGM
14.79 USD
-0.61
(-3.953%) ⇩
(April 21, 2026, 11:03 a.m.
EDT)
Short-term: ★★☆☆☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 10:43 p.m. EDT
Trevi Therapeutics is showing signs of a tactical bottoming pattern. The POC has confirmed a multi-day run-back that consolidated in the low $13s, supported by a massive cash infusion ($150M) that effectively creates a temporary price floor regardless of the negative forecasting model signals. While the macro forecast indicates a -9% trend, the options flow at deep strikes and the analyst 'strong buy' bias suggest this specific dip is being treated as a buying opportunity rather than a trend continuation. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.078841 |
| AutoETS | 0.083421 |
| MSTL | 0.085695 |
| AutoTheta | 0.096136 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 42% |
| H-stat | 19.11 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.109 |
| Excess Kurtosis | -0.22 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.411 |
| Market Cap | 2,070,559,488 |
| Forward P/E | -26.18 |
| Beta | 1.00 |
| Website | https://www.trevitherapeutics.com |
As of April 18, 2026, 10:43 p.m. EDT: Options activity shows significant Call buying in the $9.00 and $13.00 strikes for the April 17 expiration, establishing substantial Open Interest (OI) as the stock approaches current ATM levels. However, deep OI is clustered lower at $7.00 and $11.00. The femulti-year dates reveal a distinct 'flooring' strategy with massive Call OI at $10.00-$15.00 for 2027/2028, but notable Put activity at deep strikes ($3.00) suggests hedging against a severe decline or a target of sub-$5 price. IV skew remains low across most strikes, indicating a lack of immediate fear premium despite the short-term deadline pressure.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.5370677 |
| Address1 | 195 Church Street |
| Address2 | 16th Floor |
| All Time High | 16.12 |
| All Time Low | 0.46 |
| Ask | 18.89 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 1,978,740 |
| Average Daily Volume3 Month | 1,492,501 |
| Average Volume | 1,492,501 |
| Average Volume10Days | 1,978,740 |
| Beta | 0.996 |
| Bid | 11.05 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 1.428 |
| City | New Haven |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 5 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 14.79 |
| Current Ratio | 19.659 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 15.52 |
| Day Low | 14.71 |
| Debt To Equity | 0.411 |
| Display Name | Trevi Therapeutics |
| Earnings Call Timestamp End | 1,773,779,400 |
| Earnings Call Timestamp Start | 1,773,779,400 |
| Earnings Timestamp | 1,773,777,600 |
| Earnings Timestamp End | 1,778,184,000 |
| Earnings Timestamp Start | 1,778,184,000 |
| Ebitda | -49,184,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -36.39 |
| Enterprise Value | 1,789,810,944 |
| Eps Current Year | -0.43 |
| Eps Forward | -0.565 |
| Eps Trailing Twelve Months | -0.32 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 11.918 |
| Fifty Day Average Change | 2.8719997 |
| Fifty Day Average Change Percent | 0.24098 |
| Fifty Two Week Change Percent | 153.70677 |
| Fifty Two Week High | 16.12 |
| Fifty Two Week High Change | -1.3300009 |
| Fifty Two Week High Change Percent | -0.082506254 |
| Fifty Two Week Low | 5.38 |
| Fifty Two Week Low Change | 9.41 |
| Fifty Two Week Low Change Percent | 1.7490705 |
| Fifty Two Week Range | 5.38 - 16.12 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,557,235,800,000 |
| Float Shares | 105,981,675 |
| Forward Eps | -0.565 |
| Forward P E | -26.17699 |
| Free Cashflow | -27,859,000 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 34 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00627 |
| Held Percent Institutions | 0.95819 |
| Implied Shares Outstanding | 139,997,271 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut. |
| Long Name | Trevi Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 2,070,559,488 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_225357348 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -42,759,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,155,257,987 |
| Number Of Analyst Opinions | 11 |
| Open | 15.43 |
| Operating Cashflow | -42,089,000 |
| Operating Margins | 0.0 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 203 304 2499 |
| Previous Close | 15.4 |
| Price Eps Current Year | -34.395348 |
| Price Hint | 2 |
| Price To Book | 10.357143 |
| Profit Margins | 0.0 |
| Quick Ratio | 19.412 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.18182 |
| Region | US |
| Regular Market Change | -0.60999966 |
| Regular Market Change Percent | -3.9533355 |
| Regular Market Day High | 15.52 |
| Regular Market Day Low | 14.71 |
| Regular Market Day Range | 14.71 - 15.52 |
| Regular Market Open | 15.43 |
| Regular Market Previous Close | 15.4 |
| Regular Market Price | 14.79 |
| Regular Market Time | 1,776,783,801 |
| Regular Market Volume | 416,983 |
| Return On Assets | -0.2026 |
| Return On Equity | -0.3023 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 139,997,271 |
| Shares Percent Shares Out | 0.1191 |
| Shares Short | 15,295,203 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 16,813,915 |
| Short Name | Trevi Therapeutics, Inc. |
| Short Percent Of Float | 0.1369 |
| Short Ratio | 11.12 |
| Source Interval | 15 |
| State | CT |
| Symbol | TRVI |
| Target High Price | 27.0 |
| Target Low Price | 16.0 |
| Target Mean Price | 21.54545 |
| Target Median Price | 21.0 |
| Total Cash | 188,260,000 |
| Total Cash Per Share | 1.466 |
| Total Debt | 753,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.32 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 10.333025 |
| Two Hundred Day Average Change | 4.456975 |
| Two Hundred Day Average Change Percent | 0.43133304 |
| Type Disp | Equity |
| Volume | 416,983 |
| Website | https://www.trevitherapeutics.com |
| Zip | 6,510 |